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A B S T R A C T
Background
Little information exists on the impact of highly active antiretroviral therapy (HAART) on
health-care provision in South Africa despite increasing scale-up of access to HAART and
gradual reduction in HAART prices.
Methods and Findings
Use and cost of services for 265 HIV-infected adults without AIDS (World Health Organization
[WHO] stage 1, 2, or 3) and 27 with AIDS (WHO stage 4) receiving HAART between 1995 and
2000 in Cape Town were compared with HIV-infected controls matched for baseline WHO
stage, CD4 count, age, and socioeconomic status, who did not receive antiretroviral therapy
(ART; No-ART group). Costs of service provision (January 2004 prices, US$1¼7.6 Rand) included
local unit costs, and two scenarios for HAART prices for WHO recommended first-line regimens:
scenario 1 used current South African public-sector ART drug prices of $730 per patient-year
(PPY), whereas scenario 2 was based on the anticipated public-sector price for locally
manufactured drug of $181 PPY. All analyses are presented in terms of patients without AIDS
and patients with AIDS.
For patients without AIDS, the mean number of inpatient days PPY was 1.08 (95% confidence
interval [CI]: 0.97–1.19) for the HAART group versus 3.73 (95% CI: 3.55–3.97) for the No-ART
group, and 8.71 (95% CI: 8.40–9.03) versus 4.35 (95% CI: 4.12–5.61), respectively, for mean
number of outpatient visits PPY. Average service provision PPY was $950 for the No-ART group
versus $1,342 and $793 PPY for the HAART group for scenario 1 and 2, respectively, whereas
the incremental cost per life-year gained (LYG) was $1,622 for scenario 1 and $675 for scenario
2. For patients with AIDS, mean inpatients days PPY was 2.04 (95% CI: 1.63–2.52) for the HAART
versus 15.36 (95% CI: 13.97–16.85) for the No-ART group. Mean outpatient visits PPY was 7.62
(95% CI: 6.81–8.49) compared with 6.60 (95% CI: 5.69–7.62) respectively. Average service
provision PPY was $3,520 for the No-ART group versus $1,513 and $964 for the HAART group
for scenario 1 and 2, respectively, whereas the incremental cost per LYG was cost saving for
both scenarios. In a sensitivity analysis based on the lower (25%) and upper (75%) interquartile
range survival percentiles, the incremental cost per LYG ranged from $1,557 to $1,772 for the
group without AIDS and from cost saving to $111 for patients with AIDS.
Conclusion
HAART is a cost-effective intervention in South Africa, and cost saving when HAART prices
are further reduced. Our estimates, however, were based on direct costs, and as such the actual
cost saving might have been underestimated if indirect costs were also included.
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Introduction
South Africa is experiencing an HIV epidemic with
enormous social and economic consequences. Recent esti-
mates suggest that between 4.5 and 6.2 million of the 43
million South Africans are infected with HIV-1 [1]. There
were 370,000 AIDS deaths during 2003 [1], and the cumulative
projected AIDS mortality for 2010 is 4–7 million in absence
of a highly active antiretroviral therapy (HAART) programme
[2]. The largest impact of HIV on the public health sector lies
in the hospital sector [3]. In the year 2000, HIV-related
admissions amounted to 24% of all public hospital admis-
sions [4] and 12.5% of the total public health budget [5]. Cost
of inpatient and ambulatory health care of both private and
public health-care sectors is expected to rise rapidly [5].
The cost-effectiveness of HAART, in terms of reducing
HIV-related morbidity and mortality, has been documented
in industrialized countries [6–12]. The introduction of
combination HAART into routine clinical care in these
countries has been associated with a shift from inpatient to
outpatient-based hospital care [11–17]. Until recently the
prevailing assumption was that the public sector of the South
African health-care system was unable to afford the intro-
duction of antiretroviral therapy (ART) in routine clinical
care. However, the government of South Africa recently
announced its commitment towards creating the necessary
conditions for introducing ART into the public health sector
[18]. In addition, the price of HAART for resource-poor
countries decreased markedly since the year 2000 [19,20]. The
South African Department of Health has recently awarded
contracts for the supply of ART drugs to public health
facilities countrywide to international pharmaceutical com-
panies [21]. This tender is expected to reduce HAART price
to $181 per patient-year (PPY).
The aim of this study was to compare use and cost of HIV-
1–related service provision between patients receiving
HAART and a comparison group not receiving ART, and
assess the cost effectiveness of HAART.
Methods
Study Population
This study was based on the Cape Town AIDS Cohort
(CTAC); a prospective cohort study which has been described
previously [22,23]. In brief, patients of this cohort were
accrued from the HIV clinics afﬁliated to the University of
Cape Town, who were referred from a wide range of primary
HIV health-care providers. During the study period 1st
January 1995 to 31st December 2000, HAART was not
available in the publicly funded South African health-care
sector. All patients in this study accessed HAART through the
participation in the international HAART multicentre phase
III clinical trials, as approved by the Research Ethics
Committee of the University of Cape Town.
For the purpose of this study, all patients who participated
in the clinical trials and received at least three ART drugs—a
non-nucleoside reverse transcriptase inhibitor or protease
inhibitor together with two nucleoside analogues or three
nucleoside analogues—were included as the treated arm of
the study (HAART group). Patients were excluded from the
clinical trials if they were active injecting-drug users, were
diagnosed with an acute opportunistic infection at the time
of recruitment, were reported to have signiﬁcant laboratory
abnormalities, or if they were treated with immune-modulat-
ing or systemic chemotherapeutic agents. Lactating or
pregnant women were also excluded. The trial visit schedule
was usually at weeks 2, 4, and 8 and then every two to three
months thereafter.
Patients who did not participate in these clinical trials and
never had access to ART throughout the study period (No-
ART group) but received other HIV-related care were the
sample from which a ‘‘comparator’’ group was identiﬁed for
the HAART group.
At each clinic visit, all patients were routinely examined for
HIV related manifestations and staged using the World
Health Organization (WHO) clinical HIV staging system
[24]. HIV-1 infection was diagnosed by enzyme-linked
immunosorbent assay (ELISA) tests and conﬁrmed by West-
ern blot or a second enzyme-linked immunosorbent assay
test. Viral load (which was available only for the HAART
group) was determined by reverse transcriptase-polymerase
chain reaction (Amplicor; Roche Molecular Systems, Branch-
burg, New Jersey, United States) and CD4þ count, measured
by ﬂow cytometry (Beckman Coulter, Miami, Florida, United
States).
Analysis
This analysis calculated the use and cost of HIV service
provision and compared the clinical outcome, in terms of
disease progression or life year gained (LYG) by clinical stage
of HIV infection, between patients receiving HAART and a
matched comparison group who did not receive ART (No-
ART group). Patients were classiﬁed as either being non-AIDS
(WHO stages 1, 2, or 3) or AIDS (WHO stage 4) patients.
Several strategies were employed to ensure that the two
groups studied were clinically, immunologically, and socio-
economically similar and matched for the same variables used
to recruit the HAART group into the clinical trials. Logistic
regression models were ﬁtted to identify factors associated
with receiving HAART in this cohort using SAS GENMODE
procedure with logit link function and binomial error
distribution [25]. HAART patients were individually matched
with randomly selected No-ART patients on the basis of
variables independently associated with the likelihood of
receiving HAART. The socioeconomic status of each patient
was classiﬁed into ‘‘low’’ or ‘‘high’’, using a composite index
developed by the Cape Metropolitan Council [26]. A
subgroup logistic regression analysis was performed for the
HAART group, to examine whether the likelihood of
hospitalisation differed by HAART class.
To examine for residual confounding, the matched case–
control data were analysed using a conditional logistic
regression model, stratiﬁed by matching variables. The model
was ﬁtted using the SAS PHREG procedure with discrete
logistic model. All data analyses were performed in SAS
version 8.02. v2 was used to compare categorical variables,
and the non-parametric median test was used to compare
continuous non-normally distributed variables. All p-values
quoted are two sided, with a p-value , 0.05 considered as
signiﬁcant.
Use and Cost of Services
Information on inpatient and outpatient care was obtained
from the computerized hospital information systems supple-
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mented by case notes. The mean number of inpatient days
and outpatient visits PPY were calculated for the non-AIDS
(WHO stage 1, 2, and 3) and AIDS (WHO stage 4) WHO
clinical stages for both HAART and No-ART groups. A
patient-year was deﬁned as 365.25 days of follow up and
methods used for calculating the mean use of services were
similar to those used in other studies [12,16,17,27]. The
denominator consisted of the total duration of follow up for
all patients seen during the study period and numerators
were calculated by summing the use of each service. Mean and
95% conﬁdence intervals (CI) of inpatient and outpatient
service use PPY by WHO stage were calculated for the two
groups using the binomial distribution, and were compared
between the two groups by calculating the odds ratio (OR) of
the use of inpatient and outpatient services, using the No-
ART group as a reference group.
The costs of hospital HIV service provision were calculated
from a public health-care system perspective [28–30]. Unit
costs were obtained from a detailed costing study of HIV
inpatient and outpatient care conducted in the year 2000
[31], and were adjusted for inﬂation to ﬁnancial year 2004
prices using the South African Consumer Price Index [32].
Prices were converted from South African Rand to US dollars
using the average exchange rate for 2004 (US dollars ¼ 7.6
Rand) [33]. The unit cost was $215 for an inpatient day and
$33 for an outpatient visit and included costs for tests
including CD4 counts, procedures, and non-ART drug costs.
The non-ART drugs included all drugs other than ART
dispensed to the patients during the course of care, including
treatment and prophylaxis for opportunistic infections. Mean
inpatient days and outpatient visits PPY were multiplied by
their respective unit costs to estimate the PPY cost of service
provision.
ART prices used in this study are those currently available
to the public health-care sector (Ministry of Health, Provin-
cial Administration of the Western Cape). HAART drug-price
scenarios presented were (1) present public sector prices,
which amounted to $730 per annum, and (2) anticipated
public sector price for locally manufactured drugs, which
amounted to $181 per annum, for the WHO-recommended
regimen for resource-limited settings [34].
To estimate the total cost of service provision PPY for
HAART patients for the two scenarios, average ART drug
costs PPY were added to the average inpatient and outpatient
PPY costs. In sensitivity analysis, minimum and maximum
ART drug PPY costs for the two scenarios were also added to
the lower and upper limit of the 95% CI: inpatient and
outpatient PPY cost of care to provide a range of costs. Viral
load was not measured for the No-ART group because it was
not available in publicly funded institutions during the study
period and, therefore, PPY cost of viral-load investigation of
$79 (D. Roditti, personal communication) was only added to
the annual cost of service provision for the HAART group.
Cost of LYG by WHO Stage of HIV Infection
Progression times were calculated from date of entry into
non-AIDS (WHO stage 1, 2, or 3) to date of progression to
AIDS (WHO stage 4) or death, and from initial diagnosis of
AIDS (WHO stage 4) to death for AIDS patients. Patients not
known to have progressed during follow-up were censored at
either the most recent visit to the clinic or when lost to
follow-up. Median progression times were estimated using
the product-limit Kaplan-Meier survival method, and these
were compared for the HAART and No-ART groups using
log-rank test. Due to the small number of individuals who
progressed during the follow-up period, median and inter-
quartile ranges (IQR) for time to progression to AIDS or
death were extrapolated from the product-limit time to
failure estimates using the maximum likelihood least squares
method. The progression-free times for non-AIDS and AIDS
patients for each group were multiplied by the average PPY
cost of service provision, and the additional life years gained
of non-AIDS and AIDS groups was calculated as the
incremental cost per LYG, based on the difference in the
estimated median progression times of the two groups [27].
Because discounting health beneﬁts remains controversial
[35], only non-discounted estimates are presented. However,
given the relatively short time in each WHO stage, it is
unlikely that an analysis with a non-zero discount rate would
yield qualitatively different results than those presented here.
Sensitivity Analysis
Robustness of results was assessed in a sensitivity analysis;
accounting for variances associated with treatment effects
and total cost of service provision. IQRs between the lower
(25%) and upper (75%) progression-free times percentiles of
the non-AIDS and AIDS patients were multiplied by the
average and 95% CI of the cost of service provision, and the
incremental cost per LYG was calculated.
Results
Study Sample
Of the 1,630 patients in the cohort, 292 patients (265 non-
AIDS and 27 with AIDS) received HAART through partic-
ipation in the clinical trials. The rest of the patients (n ¼
1,328; 1,093 non-AIDS and 235 with AIDS) did not have access
to ART during the study period and comprised the
population from which the No-ART comparator group for
the 292 patients who received HAART was identiﬁed.
Baseline CD4 count, WHO stage, age, and socioeconomic
status were independently associated with the likelihood of
receiving HAART (Table 1), but gender was not, and
therefore this variable was not considered in further analyses.
Matching was therefore based on WHO stage, CD4 count
(,200, 200–350, and .350 cells/ll), age (less than the median
age or equal to the median age or greater of the non-AIDS
and AIDS groups respectively) and socioeconomic status (low
or high socioeconomic status).
HAART drug classes were not independently associated
with increased risk of hospitalisation (Table 2) and were
therefore analysed as one category. The characteristics of the
ﬁnal study population of the 292 patients who received
HAART and the 292 matched No-ART patients are described
in Table 3.
The Non-AIDS Population (WHO Stage 1, 2, or 3)
The matched non-AIDS group included 265 patients both
in the HAART and No-ART group. Approximately one-third
of the patients in the two groups had a baseline CD4 count
,200 cell/ll and (49.4%) were of low socioeconomic status.
Median age at inclusion into study did not differ in the two
groups; 32 y, [IQR: 28–39 y] in the HAART group versus 32 y
[IQR: 28–40 y] in the No-ART group (median test p ¼ 0.48).
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Although not matched for, gender distribution did not differ
statistically in the two groups (v2 ¼ 0.07, p ¼ 0.79; Table 3).
Median progression time was signiﬁcantly longer in the
HAART group compared with the No-ART group at 4.1 and
3.0 y respectively (log-rank test v2¼ 36.6, p , 0.001; Figure 1).
Use and Cost of Services and Cost per LYG
Patients on HAART had 1.08 (95% CI: 0.97–1.19) mean
inpatient days, signiﬁcantly fewer than the 3.75 d (95% CI:
3.55–3.97) of the No-ART group; v2¼ 147, OR¼ 0.29, 95% CI:
0.23–0.36, p , 0.001; but had signiﬁcantly more outpatient
visits of 8.71 (95% CI: 8.40–9.03) compared with 4.35 (95% CI:
4.12–5.61); v2¼ 145, OR¼ 2.00, 95% CI: 1.78–2.25, p , 0.0001
(Table 4). The average PPY inpatient cost in the HAART
group was signiﬁcantly less than that for the No-ART group,
while the average costs of outpatient visits PPY for the No-
ART group were less than those for the HAART group (Table
4).
Based on the two HAART price scenarios, the average cost
of service provision PPY for the HAART group ranged from a
minimum of $760 to $1,377 PPY, with scenario 2 having the
lowest service provision cost (Table 4). The incremental cost
per LYG for median progression time was $1,622 (95% CI:
1,607–1,627) for scenario 1 and $675 (95% CI: 659–679) for
scenario 2 (Table 5). When a sensitivity analysis was
performed based on the IQR of the progression times, the
incremental cost per LYG varied between $1,578 (95% CI:
1,557–1,581) and $1,759 (95% CI: 1,748–1,772) for the 25th
and 75th percentiles respectively (Table 5).
The AIDS Population (WHO Stage 4)
The AIDS population included 27 patients in each group.
The majority of patients in the two groups presented with a
CD4 count ,200 cell/ll (77%), and 40.74% were of low
socioeconomic status. Median age did not differ in the two
groups; 35 y (IQR: 32–41) in the HAART group versus 37 y
(IQR: 33–50) in the No-ART group (median test p ¼ 0.27).
Gender distribution, with 63% and 70.4% males in the
HAART and No-ART groups respectively, was not signiﬁ-
cantly different in the two groups (v2 ¼ 0.33, p ¼ 0.56) (see
Table 3). Median progression time was signiﬁcantly longer in
the HAART group compared with the No-ART group; at 3.1
and 1.4 y respectively (log-rank v2¼ 5.28, p ¼ 0.02; Figure 2).
Use and Cost of Services and Cost per LYG
Patients on HAART had signiﬁcantly fewer mean PPY
inpatient days at 2.04 d (95% CI: 1.63–2.52) compared with
15.36 d (95% CI: 13.97–16.85) for the No-ART group (v2 ¼
1,019, OR ¼ 0.13, 95 CI: 0.11–0.15, p , 0.0001). Mean
outpatient visits PPY in the two groups did differ signiﬁ-
cantly; at 7.62 (95% CI: 6.81–8.49) for the HAART group
compared with 6.60 (95% CI: 5.69–7.62) for the No-ART
Table 1. Univariate and Multivariate Logistic Regression Analyses of Factors Associated with the Likelihood of Receiving HAART
Characteristic Subcategory Univariate Analysis Multivariable Analysis
OR 95% CI: p-Value OR 95% CI: p-Value
CD4 count (cells/ll) ,200 1.00 0.73–1.38 0.98 1.14 0.82–1.60 0.44
200–350 2.05 1.49–2.84 ,0.001 2.14 1.54–2.99 ,0.001
.350 1 1
WHO stage Non-AIDS 2.10 1.39–3.21 0.001 2.24 1.43–3.49 ,0.001
AIDS 1 1
Age ,32 0.68 0.53–0.88 0.004 0.70 0.54–0.92 0.01
32 1 1
Socioeconomic status Low status 0.44 0.34–0.56 ,0.001 0.43 0.33–0.56 ,0.001
High 1 1
Gender status Male 1.26 0.98–1.63 0.08 1.07 0.82–1.40 0.64
Female 1 1
OR, odds ratio.
DOI: 10.1371/journal.pmed.0030004.t001
Table 2. Logistic Regression Analysis of Factors Associated with Hospitalisation among the Treated Group
Variable Subcategory Univariate Analysis Multivariate Analysis
RR 95% CI p-Value RR 95% CI p-Value
CD4 count (cells/ll) ,200 2.04 1.02–4.10 0.04 1.77 0.86–3.64 0.12
200–350 1.31 0.64–2.66 0.46 1.22 0.59–2.52 0.59
.350 1 1
Viral load (log10 copies/ll) 0.70 0.46–1.06 0.09 0.77 0.50–1.19 0.24
HAART drug class NNRTI (n ¼ 154, 52.7%) 1.23 0.71–2.14 0.13 1.16 0.67–2.04 0.59
TNRTI (n ¼ 21, 7.2%) 0.53 0.15–1.93 0.34 0.59 0.16–2.16 0.42
PI (n ¼ 117, 40.1%) 1 1
NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; RR, risk ratio; TNRTI, triple nucleoside reverse transcriptase inhibitor.
DOI: 10.1371/journal.pmed.0030004.t002
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group; v2 ¼ 7.3, OR ¼ 1.15, 95% CI: 1.04–1.28, p ¼ 0.007,
though not as substantially as for the non-AIDS group (see
Table 4). The average inpatient cost PPY in the HAART
group was signiﬁcantly less than that for the No-ART group,
but the average costs of outpatient visits PPY in the groups
were not signiﬁcantly (see Table 4).
Based on the two HAART price scenarios, the average cost
of service provision PPY for the HAART group ranged from a
minimum of $850 to $1,645 PPY, with the lowest care cost
observed for scenario 2 (see Table 4). For patients diagnosed
with AIDS, the incremental cost per LYG for the median
progression time was cost saving for both HAART price
scenarios (Table 5). When a sensitivity analysis was performed
based on the IQR of the progression times, the incremental
cost per LYG varied between $71 (95% CI: 43–111) and cost
saving for the 25th and 75th progression-free time percentiles
respectively (Table 5).
Discussion
This study, employing methods used in similar studies from
industrialized countries [27], provides a unique contempora-
neous comparison of the use, cost, and outcome of hospital
service provision for a group of HIV-infected patients in
Cape Town receiving HAART compared with an immuno-
logically, clinically, and socioeconomically similar group of
patients who did not receive ART. Use of HAART was
associated with decreased disease progression, AIDS, and
death. The HAART group used fewer inpatient services than
the No-ART group, and the magnitude of these changes did
not differ by HAART regimens used in this study. The
Table 3. Baseline Demographic and Clinical Characteristics of the Matched Non-AIDS and AIDS Groups
Variable Subcategory Non-AIDS AIDS
HAART (n ¼ 265) No-ART (n ¼ 27) HAART(n ¼ 265) No-ART (n ¼ 27)
n (%) n (%) n (%) n (%)
CD4 count ,200 cells/ll 81 (30.6) 81 (30.6) 21 (77.7) 21 (77.7)
200–350 cells/llL 110 (41.5) 110 (41.5) 1 (3.8) 1 (3.8)
.350 cells/lL 74 (27.9) 74 (27.9) 5 (18.5) 5 (18.5)
Median age (IQR) 32 (28–39) 32 (28–40) 35 (32–41) 37 (33–50)
Socio-economic status Low status 131 (49.4) 131 (49.4) 11 (40.74) 11 (40.74)
High status 134 (50.6) 134 (50.6) 16 (59.26) 16 (59.26)
Gender Male 142 (53.60) 145 (54.7) 17 (63) 19 (70.4)
Female 123 (46.4) 120 (45.3) 10 (37) 8 (29.6)
IQR, interquartile range.
DOI: 10.1371/journal.pmed.0030004.t003
Figure 1. Progression of HIV-Infected Individuals from Non-AIDS Stages (WHO Stage 1, 2, or 3) for Patients on HAART and Not on ART
The solid line indicates patients on HAART, and the dotted line indicates patients not on ART.
DOI: 10.1371/journal.pmed.0030004.g001
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reduction in use of inpatient services, which has been
observed in similar studies in industrialized countries [10–
15], was most likely due to a reduction in morbidity and
mortality [6,12]. The use of services increased for both groups
with increased severity of HIV infection, resulting in an
increased cost of service provision. The increased use of
inpatient services for patients with AIDS is most likely related
to AIDS-related events or their terminal phase of their illness
[36–41]. In Zimbabwe, medical insurance claims of privately
insured HIV-infected patients in the last few months of their
lives were 700% higher than that of uninfected patients in the
same age group [42].
To date, very few cost-effectiveness studies have been
performed on HAART in a South African setting [43]. The
incremental cost per LYG ranged from being cost saving to
$1,772. The cut-off point for what constitutes a cost-effective
intervention per outcome measure varies from society to
another. For instance, the cost-effective cut-off point in the
United States is currently considered to be $50,000 per
outcome measure and £30,000 in the United Kingdom [30].
To date such a consensus on what would constitute a realistic
threshold for South Africa has not yet emerged, but a cut-off
of twice the per capita gross domestic product (GDP) has
been suggested as a reasonable cut-off point for developing
countries [44]. For the year 2004, the per capita gross
domestic product in South Africa was $3,480, and therefore
this threshold would amount to $6,960 [45]. The cost per LYG
of two HAART cost scenarios for the non-AIDS and AIDS
patients showed that introducing HAART in this hospital
setting would be a very cost-effective intervention. However,
it is clear that the cost-effectiveness ratios were very sensitive
to the price of HAART. If prices of the awarded tender could
be achieved, the introduction of HAART will be a very cost-
effective intervention in Cape Town and probably in similar
settings in sub-Saharan Africa, because HIV accounts for
between 40% and 70% of the public sector inpatient service
provision in the region [3,36–40].
Concern has been expressed that increased access to
HAART in sub-Saharan Africa will result in the widespread
viral resistance due to poor adherence [46]. Studies
Table 4. Mean Number of Inpatient Days, Outpatient Visits, and Associated Costa PPY
Variable Non-AIDS AIDS
HAART No-ART HAART No-ART
Mean number of inpatient days PPY (95% CI) 1.08 (0.97–1.19) 3.75 (3.55–3.97) 2.04 (1.63–2.52) 15.36 (13.97–16.85)
ORa ¼ 0.29 (95% CI: 0.23–0.36) OR ¼ 0.13 (95% CI: 0.11–0.15)
Average inpatient days cost (95% CI) $232 (209–256) $806 (763–854) $439 (351–542) $3,302 (3,004–3,623)
Mean number of outpatient visits PPY (95% CI) 8.71 (8.40–9.03) 4.35 (4.12–5.61) 7.62 (6.81–8.49) 6.60 (5.69–7.62)
OR ¼ 2.00 (95% CI: 1.78–2.25) OR ¼ 1.15 (95% CI: 1.04–1.28)
Average outpatient visits cost (95% CI) $287 (277–298) $144 (136–185) $251 (225–280) $218 (188–252)
Average total cost PPY (95% CI)
Scenario 1 (current public sector price ¼ $730) $1,342 (1,309–1,377) $950 (899–1,039) $1,513 (1,399–1,645) $3,520 (3,192–3,875)
Scenario 2 (anticipated tender price ¼ 181) $793 (760–828) $950 (899–1,039) $964 (850–1,096) $3,520 (3,192–3,875)
aOdds ratio (OR) uses the No-ART group as baseline risk.
DOI: 10.1371/journal.pmed.0030004.t004
Table 5. Incremental Cost-Effectiveness Ratio (US$) for Current ART Rollout Prices (US$730 Per Annum—Scenario 1) and Anticipated
Tender Prices (US$181 Per Annum—Scenario 2), Comparing HAART and No-ART Groups for Non-AIDS and AIDS Groups at 25th, 50th
(Median), and 75th Progression-Free Times Percentiles
Survival Quartile Group Survival Time (d) ICER (95% CI)
Scenario 1a Scenario 2b
25% Non-AIDS HAART (1391) $1,578 (1,557–1,581) $698 (676–701)
No-ART (523)
AIDS HAART (739) $71 (43–111) Cost-saving
No-ART (309)
Median 50% Non-AIDS HAART (2,641) $1,622 (1,607–1,627) $675 (659–679)
No-ART (1,111)
AIDS HAART (1,120) Cost-saving Cost-saving
No-ART (510)
75% Non-AIDS HAART (3,891) $1,759 (1,748–1,772) $608 (597–621)
No-ART (2,035)
AIDS HAART (1,561) Cost-saving Cost-saving
No-ART (980)
aCurrent rollout prices.
bAnticipated tender prices.
ICER, incremental cost-effectiveness ratio.
DOI: 10.1371/journal.pmed.0030004.t005
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performed in a number of sub-Saharan African countries,
however, have shown that the proportion of individuals
maintaining viral suppression is comparable to that reported
from developed countries [47–49].
This study did have a number of limitations. Because
HAART was not used in routine clinical practice, we had to
compare a group of patients enrolled in clinical trials with a
control group that was not part of the trials. Individuals who
take part in clinical trials have to fulﬁl certain entry criteria,
as well as to conform to well-deﬁned protocols and scheduled
attendances. It is therefore difﬁcult to exclude the possibility
that a selection bias might have resulted from the inclusion/
exclusion criteria of these clinical trials. However, the No-
ART control group was selected on the basis of clinical,
socioeconomic, and immunologic characteristics similar to
those individuals recruited into the HAART trials conducted
in this study. The frequency of inpatient and outpatient
services utilization of the HAART and No-ART patients in
this study is similar to that reported by UK and Canadian
observational studies [12,27]. However, in this study, the
sample is relatively small for the AIDS group.
This study was focused on hospital services provided at the
level of a teaching hospital. Therefore the costs incurred
through primary, community, or secondary hospital care
were not included, but this reﬂected the conﬁguration of
services available to the majority of HIV-infected people in
Cape Town at the time of the study. Similarly, the costs
included were direct costs only and did not incorporate the
indirect or intangible costs, such as loss of productivity or
quality of life associated with this illness, because currently no
such data exist in South Africa. Some studies from the United
Kingdom have demonstrated that from a public sector
perspective, indirect costs can comprise between 58% and
124% of direct treatment costs for HAART or between 45%
and 102% from a societal perspective [30]. If these costs were
all included, it is likely that the cost-effectiveness ratio would
even be more favourable. Our estimates did not incorporate
the costs of providing the infrastructure required to support
appropriate HAART provision in rollout programmes.
However the rollout programmes were designed to start
from settings where infrastructure currently exists, which
would predominantly be urban. Recent reports estimated
that if the public sector included HAART as part of a package
of HIV treatment and care in the year 2003, the cost would be
1.2% of the South African GNP, which is unlikely to push
health-care expenditure beyond prudent levels [50,51].
The recent commitment towards scale-up of HAART in
South Africa as part of HIV treatment and care has been an
important and positive development. The urgent need to
introduce HAART as part of routine HIV treatment and care
was recently re-iterated in a World Bank report, which
indicated that if this is not done soon, failure to do so would
have devastating effects on this and future generations of
South Africans [52].
Although the primary rationale for wider access to HAART
is humanitarian, a national HAART programme targeting
patients with symptomatic HIV disease, using low-cost
HAART prices would also signiﬁcantly decrease hospital
services utilization by HIV-infected patients, resulting in
either health expenditure saving by cost deferral or freeing
substantial resources for health care of non-HIV patients.
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Patient Summary
Background. The number of cases of AIDS continues to increase
worldwide; the disease is a major threat to humanity, with Africa facing
the very worst problems. In South Africa alone there were 370,000 AIDS
deaths in 2003. AIDS is caused by a type of retrovirus—the human
immunodeficiency virus (HIV). Highly active antiretroviral treatment
(HAART) is a treatment that uses a combination of three or more
antiretroviral drugs that attack different parts of the virus. HAART is
expensive, making it difficult for poor countries to provide treatment for
all who need it. Prices are falling, however, and South Africa is one
country where efforts are now being made to improve access to
treatment.
Why Was This Study Done? The cost-effectiveness of HAART has been
studied in developed countries, but developing countries also need to
know how much it is going to cost their health services if they introduce
HAART, and whether there will be financial savings because of switching
to a more effective treatment.
What Did the Researchers Do and Find? During the study period
(January 1995 to 31 December 2000), HAART was not available in the
publicly funded South African health-care sector. The study, funded by
the drug manufacturer Bristol-Myers Squibb, took place in HIV clinics
affiliated with the University of Cape Town. The researchers compared
the cost of services for 292 patients who were given HAART with the
costs for a comparison group (with the same number of patients) who
were not given any antiretroviral drugs. Twenty-seven patients in each
group had AIDS; the others were HIV-infected but did not have AIDS. The
researchers calculated costs per patient year (PPY) and per life-year
gained (LYG), i.e., the total cost divided by the number of extra years the
treated patients lived. Calculations were done separately for patients
with AIDS and those without AIDS. Patients on HAART required fewer
hospital admissions. Depending on how long the patient survived and
the price of antiretrovirals, it cost less to treat the HAART patients with
AIDS. For this group, the cost saving ranged from $219 to $2,116 (in U.S.
dollars). For patients without AIDS, the cost of treatment (ranging from
$597 to $1,772) was, by the South African standard of cost of living,
affordable. However, it is expected that South Africa will soon be able to
manufacture antiretroviral drugs locally and more cheaply. This would
increase the amount saved by introducing HAART.
What Does This Mean? HAART seems to be a more cost-effective way
for South African hospitals to treat HIV infection than simply waiting for
patients to come to hospital and then dealing with their symptoms.
However, it should be noted that when a person is infected with HIV and
becomes ill or dies from AIDS, it is not only hospitals that face costs. The
patient, their family, and the country suffer financially. Effective
treatment might also lower these ‘‘indirect’’ costs, but this was not an
issue examined in this research.
Where Can I Find More Information Online? For a comprehensive
source of information on HIV/AIDS:
http://www.thebody.com
The site also includes a useful section on HAART:
http : / /www.thebody .com/Forums/AIDS/ Infect ions/Archive/
NewMedications/Q12178.html
For information about the global AIDS situation and the position in
different countries:
http://www.unaids.org.
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